• Home
  • News

Sichenzia Ross Ference Carmel LLP Represents Sunshine Biopharma, Inc. in $10.0 Million Underwritten Public Offering of Common Stock

sunshine biopharma

Press Release – New York, NY – February 15, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented Sunshine Biopharma, Inc. (NASDAQ: SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, in a $10.0 Million Underwritten Public Offering of common stock. The offering consists of 71,428,571 Units, each consisting of one share of common stock or Pre-Funded Warrant to purchase one share of common stock and 0.1 Series A Warrants to purchase one share of common stock per warrant, and 0.2 Series B Warrants to purchase one share of common stock per warrant. The public offering price per Unit is $0.14 (or $0.139 for each Unit with a Pre-Funded Warrant, which is equal to the public offering price per Unit with a share of common stock to be sold in the offering minus an exercise price of $0.001 per Pre-Funded Warrant). The gross proceeds of the transaction is $10 million. 

The Sichenzia Ross Ference Carmel LLP team was led by partners Gregory Sichenzia, Darrin Ocasio, Jeff Cahlon, and associate Christian Lichtenberger.